A panel of international medical and scientific experts on garlic has concluded that there is ample evidence to warrant the granting of an official health claim recognizing the numerous benefits of garlic in the prevention of cardiovascular disease. As a result of its deliberations, the panel has urged that a proposal for such a health claim should be submitted to the US Food and Drug Administration for its review and consideration.
This group of specialists met recently at a Cardiovascular Garlic Symposium, held in Berlin, Germany, to discuss the broad scientific evidence that garlic powder LI 111 can not only prevent the most relevant causes of heart disease, but may even reverse them. This proprietary standardized garlic extract was scrutinized extensively by international research, resulting in 42 clinical trials focused on the prevention and reversal of cardiovascular disease.
Garlic powder LI 111 specifically has superior scientifically-documented record
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze